Phase I Study and Pilot Efficacy Analysis of Entinostat, a Novel Histone Deacetylase Inhibitor, in Chinese Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer

Pembrolizumab for Early Triple-Negative Breast Cancer

(2020) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epigenetic Regulation of Multidrug Resistance Protein 1 and Breast Cancer Resistance Protein Transporters by Histone Deacetylase Inhibition

(2020) Dahea You et al.   DRUG METABOLISM AND DISPOSITION

Roadmap of DNA methylation in breast cancer identifies novel prognostic biomarkers

(2019) Bernardo P. de Almeida et al.   BMC CANCER

Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial

(2019) Zefei Jiang et al.   LANCET ONCOLOGY

Epigenetics of breast cancer: Biology and clinical implication in the era of precision medicine

(2018) Barbara Pasculli et al.   SEMINARS IN CANCER BIOLOGY

Histone Deacetylase Inhibitors as Anticancer Drugs

(2017) Tomas Eckschlager et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages

(2017) Jennifer L. Guerriero et al.   NATURE

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

(2016) Gabriel N. Hortobagyi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Palbociclib and Letrozole in Advanced Breast Cancer

(2016) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Challenges in the management of advanced, ER-positive, HER2-negative breast cancer

(2015) Christopher D. Hart et al.   Nature Reviews Clinical Oncology

Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor

(2013) Denise A. Yardley et al.   JOURNAL OF CLINICAL ONCOLOGY